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Hypoxia is a key parameter that controls tumor angiogenesis and
malignant progression by regulating the expression of several onco-
genicmolecules. The nonreceptor protein-tyrosine kinases Syk and
Lck play crucial roles in the signalingmechanism of various cellular
processes. The enhanced expression of Syk in normal breast tissue
but not in malignant breast carcinoma has prompted us to investi-
gate its potential role in mammary carcinogenesis. Accordingly, we
hypothesized that hypoxia/reoxygenation (H/R)mayplay an impor-
tant role in regulating Syk activation, and Lck may be involved in
this process. In this study, we have demonstrated that H/R differen-
tially regulates Syk phosphorylation and its subsequent interaction
and cross-talk with Lck inMCF-7 cells. Moreover, Syk and Lck play
differential roles in regulating Sp1 activation and expressions of
melanoma cell adhesion molecule (MelCAM), urokinase-type plas-
minogen activator (uPA), matrix metalloproteinase-9 (MMP-9),
and vascular endothelial growth factor (VEGF) in response to H/R.
Overexpression of wild type Syk inhibited the H/R-induced uPA,
MMP-9, and VEGF expression but up-regulated MelCAM expres-
sion. Our data also indicated that MelCAM acts as a tumor sup-
pressor by negatively regulating H/R-induced uPA secretion and
MMP-9 activation. Themice xenograft study showed the cross-talk
between Syk and Lck regulated H/R-induced breast tumor progres-
sion and further correlated with the expressions of MelCAM, uPA,
MMP-9, and VEGF. Human clinical specimen analysis supported
the in vitro and in vivo findings. To our knowledge, this is first
report that the cross-talk between Syk and Lck regulates H/R-in-
duced breast cancer progression and further suggests that Syk may
act as potential therapeutic target for the treatment of breast
cancer.
Hypoxia plays a crucial role in regulating breast tumor progression
through a multistep process that includes oncogene activation or inhi-
bition of tumor suppressor genes (1). Most tumors develop regions of
chronically or transiently hypoxic cells during growth (2). Hypoxic
tumor regionsmay show increased expression ofmany genes because of
hypoxia-induced activation of transcription factors (3–5). Low extracel-
lular pH, glucose depletion, high lactate levels, and regions with low
oxygen tension (6, 7) characterize most tumors. Low oxygen tension in
tumors has been associated with poor outcome, enhanced local or
locoregional spread, and enhancedmetastatic potential (8). Hypoxia is a
key parameter, whichmodulates the expression of a variety of genes that
are involved in tumor angiogenesis, malignant progression, and distant
metastasis (9). The signaling properties of reactive oxygen species are
because of the reversible oxidation of redox-sensitive target proteins
(10). The generated reactive oxygen species act as intracellular second
messengers in various signal transduction pathways and hence play a
crucial role in regulating disease and stress-induced cellular injuries
such as ischemia/reperfusion, UV irradiation, and inflammation (10).
Previous reports have indicated that areas of hypoxia/reoxygenation
(H/R)3 are a typical feature of rapidly growing andmetastasizing tumors
(11, 12). It was also demonstrated that both hypoxia and consecutive
hypoxia/reoxygenation exert a variety of influence in tumor cell biology
that ultimately regulates tumor progression (13). Earlier reports also
showed that hypoxia and H/R regulate the activation of various mito-
gen-activated protein kinase signaling pathways (13) and induce the
activation of several transcriptional factors such as HIF-1, NFB,
AP-1, and Sp1 (13–15).However, very recently it was demonstrated that
H/R rather than hypoxia alone appears to induce the expression and
activation of several oncogenicmolecules and plays an important role in
tumor progression (13, 16).
The nonreceptor protein-tyrosine kinase Syk is widely expressed in
hematopoietic cells (17, 18). It has tandem amino-terminal Src homol-
ogy 2 domains and a carboxyl-terminal kinase domain (19). The Src
homology 2 domains bind phosphorylated immunoreceptor tyrosine-
based activation motifs and hence play a significant role in immunore-
ceptor and cytokine signaling (20). The expression of Syk has also been
reported in cell lines of epithelial origin (21), but its function in these
cells is not well understood. It has been documented that Syk is com-
monly expressed in normal humanbreast tissue, benign breast lesions, and
low tumorigenic breast cancer cell lines (22). Previous data indicated that
Syk suppresses cell motility and NFB-mediated urokinase-type plas-
minogen activator (uPA) secretion by inhibiting phosphatidylinositol
3-kinase activity in breast cancer cells (23). Lck, a member of the Src
family nonreceptor protein-tyrosine kinase, is mostly expressed in T
cells, breast cancer tissues, and cell lines and also in some B cells (24).
Lck binds to the cytoplasmic domain of CD4 and CD8 and plays an
essential role in T cell activation and development (25). Earlier reports
have indicated that p72Syk plays a crucial role in activation of p56Lck
through physical association and amino-terminal tyrosine phosphoryl-
ation at residues Tyr-518 and Tyr-519. Mutation of these residues to
phenylalanines abolished its activity in vitro and toward cellular sub-
strates in vivo and reduced its tyrosine phosphorylation by 90% (26).
However, the molecular mechanism by which H/R regulates Syk phos-
phorylation and its subsequent interaction with Lck leading to down-
stream signaling events in breast cancer cells are not well defined.
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MelCAM, previously known as MUC18 or MCAM, a newly recog-
nized cell adhesion molecule with an apparent molecular mass of 113
kDa, belongs to the immunoglobulin superfamily (27–29). The pres-
ence of putative binding sites for the transcription factors Sp1, AP-1,
AP-2, and cAMP-response element-binding protein in the promoter
region suggests that MelCAM expression can be modulated by exoge-
nous factors (30). At the cellular level, phorbol ester and cyclic AMP
have been shown tomodulateMelCAM expression (31). Earlier reports
have indicated that MelCAM acts differently in the progression of
breast carcinomas. It is expressed in normal and benign proliferative
breast epithelium, and its expression is frequently lost in in situ and
infiltrating breast carcinomas (32, 33). The MelCAM core promoter
contains four binding sites for the Sp1 transcription factor, and deletion
analyses have indicated that removal of all putative Sp1 sites reduced the
promoter activity by 80%, suggesting that Sp1 is an important regulator
of MelCAM expression (34). However, the molecular mechanism by
which H/R regulates Syk activation and Syk-dependent Lck-mediated
Sp1 activation leading to the regulation of MelCAM expression in
MCF-7 cells is not well defined.
Degradation of extracellular matrix plays an important role in tumor
metastasis. uPA is a member of the serine protease family that interacts
with uPA receptor and facilitates the conversion of inert zymogen plas-
minogen into widely acting serine protease plasmin (35, 36). MMP-9,
also referred as gelatinase-B, is not only associated with invasion and
metastasis but also has been implicated in angiogenesis, rheumatoid
arthritis, retinopathy, and vascular stenosis and hence is considered to
be a prioritized therapeutic target (37, 38). Several reports have indi-
cated the positive correlation between uPA/MMP-9 activation and the
metastatic potential of tumors (39). However, the molecular mecha-
nism by which H/R regulates Syk/Lck-dependent MelCAM expression
and uPA secretion and the uPA-dependent pro-MMP-9 activation in
breast carcinoma cells is not well understood. Moreover, the roles of
these molecules in regulating H/R-induced tumorigenesis and its clini-
cal implications are not well defined.
Hypoxia-induced VEGF production provides one of the main
driving forces that stimulate the angiogenesis, which accompanies
tumor progression (40, 41). To date, VEGF is considered as the key
factor that guided and regulated tumor angiogenesis (42). Tumor
cell-derived VEGF binds to its specific receptors and regulates tumor
progression through neovascularization via autocrine and paracrine
pathways (43, 44). Recent evidence suggested that the VEGF pro-
moter contains an Sp1-response element (45). However, the role of
Lck and Syk in H/R-induced VEGF expression in breast cancer is not
defined clearly.
In this study we have demonstrated the differential role of Syk and
Lck in the H/R-induced uPA, MMP-9, and VEGF expression. Our
findings suggested that H/R down-regulates Syk activation leading to
enhanced uPA, MMP-9, and VEGF expression. Furthermore, over-
expression of Syk restored H/R-induced down-regulation of Mel-
CAM expression. In hypoxic cells, Lck also physically associates with
Syk, and this association plays a crucial role in regulating the down-
stream signaling. The in vivo relevance of our study was further
validated in a xenografted nude mice model, which also supports our
in vitro findings. Clinical data also indicated that the higher grades of
tumors showed significant HIF-1 expression compared with that of
lower grades or normal breast tissue and also demonstrated an
inverse correlation between Syk/MelCAM and uPA/MMP-9/VEGF
expression, which further correlates with enhanced tumorigenic
potential and neovascularization.
EXPERIMENTAL PROCEDURES
Materials—The rabbit polyclonal anti-Syk, anti-Lck, anti-Sp1, anti-
MelCAM, anti-uPA, anti-MMP-9, anti-actin, mouse monoclonal anti-
Lck, anti-Syk, anti-phosphotyrosine antibodies, andMelCAM blocking
peptide were purchased from Santa Cruz Biotechnology. Rabbit poly-
clonal anti-VEGF was from Oncogene. Rabbit polyclonal anti-vWF
antibody was from Sigma. Rabbit polyclonal anti-HIF-1 was from
Upstate Biotechnology, Inc. Lipofectamine Plus was obtained from
Invitrogen. pp2, aminogenistein, and damnacanthal were from Calbio-
chem. The Sp1 consensus oligonucleotide was purchased from Banga-
lore Genei. Matrigel was purchased from BD Biosciences. The
[-32P]ATP was purchased from the Board of Radiation and Isotope
Technology (Hyderabad, India). The female nude mice (NMRI, nu/nu)
were from National Institute of Virology (Pune, India). All other chem-
icals were of analytical grade.
Cell Culture—TheMCF-7 cells were cultured inDulbecco’smodified
Eagle’s medium supplemented with 10% fetal calf serum, 100 units/ml
penicillin, 100 mg/ml streptomycin, and 2 mM glutamine in a humidi-
fied atmosphere of 5% CO2 and 95% air at 37 °C.
Hypoxic/Reoxygenation Cultures—The MCF-7 cells grown to 50–70%
confluence were made hypoxic in evacuation chambers by intermittent
application of vacuum and sparging with 95% N2, 5% CO2. Cells were
analyzed at this point or maintained under hypoxic conditions in the
presence of 100 mM dithionate (an O2 scavenger) at 37 °C for the indi-
cated time point. These cells were reoxygenated for the indicated peri-
ods by replacing the medium with fresh medium and incubating the
cultures in humidified atmosphere of 5% CO2 and 95% air at 37 °C.
Immunofluorescence and Immunohistochemistry—To detect the
effect of H/R on cellular localization of Syk, cells grown inmonolayer on
glass slides were induced by hypoxia for 2 h and reoxygenated for 45
min. The cells were fixed and incubated with rabbit polyclonal anti-Syk
antibody (1:50 dilution) followed by FITC-conjugated anti-rabbit IgG at
room temperature. The role of H/R in regulating Syk-Lck colocalization
was determined by immunofluorescence studies using a mixture of
mouse monoclonal anti-Syk and rabbit polyclonal anti-Lck antibody
followed by a mixture of TRITC- and FITC-conjugated IgG. The cells
were washed and mounted with coverslips. All these samples were ana-
lyzed under confocal microscopy (Zeiss).
The clinical specimens were analyzed by immunohistopathological
studies. Formalin-fixed paraffin-embedded sections (4 m) were sub-
jected to antigen retrieval, and the Syk-Lck colocalization was deter-
mined by immunofluorescence studies using a mixture of rabbit poly-
clonal anti-Syk and mouse monoclonal anti-Lck antibodies followed by
a mixture of FITC- and TRITC-conjugated IgGs. The levels of HIF-1
expression in these clinical samples were determined by Western blot
analysis. The levels of MelCAM, uPA, MMP-9, and VEGF expressions
in these sampleswere detected by immunofluorescence studies by using
their specific antibodies. The tumormicrovessel densitieswere detected
by immunostaining with anti-vWF antibody. All these samples were
analyzed under confocal microscopy (Zeiss).
Plasmids and DNA Transfection—The dominant-negative form of
Lck (DN Lck, K273R) in pcDNA3 was a kind gift from Dr. D. R. Branch
(Canadian Blood Services, Toronto, Ontario). Thewild type and kinase-
negative Syk cDNA in pcDNA 3.1 were the generous gifts from Dr.
Susette C. Mueller (Department of Oncology, Georgetown University
Medical School,Washington, D. C.). MCF-7 cells were transfected with
specific cDNAusing Lipofectamine Plus reagent (Invitrogen) according
to the manufacturer’s instructions as described previously (46). These
transfected cells were used for Syk-Lck colocalization and
interaction studies, detection of Sp1, Syk, Lck, MelCAM, uPA,
Cross-talk between Syk and Lck in Response to H/R
APRIL 21, 2006•VOLUME 281•NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 11323
 by guest, on Decem
ber 22, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
MMP-9, andVEGF byWestern blot analysis, and in vivo tumorigenicity
experiments.
Zymography Experiments—The gelatinolytic activity was measured
as described (46, 47). To examine whether H/R regulates MMP-9 acti-
vation and to investigate the effect of inhibition ofMelCAM expression
on H/R-inducedMMP-9 activation, cells were either induced with H/R
for 24 h or pretreated withMelCAM blocking peptide (50 g) and then
exposed with H/R. The conditionedmedia were collected, and the sam-
ples were analyzed by zymography as described (47). Negative staining
showed the zones of gelatinolytic activity.
Immunoprecipitation—To delineate the role of H/R in the regulation
of tyrosine phosphorylation of Syk, cells were exposed to hypoxia for 2 h
followed by reoxygenation for 0–60min. In separate experiments, cells
were pretreated with Lck inhibitors, pp2 (4 nM), aminogenistein (2M),
and damnacanthal (0.8 M), and then exposed to H/R. Cell lysates were
immunoprecipitated with rabbit polyclonal anti-Syk antibody and ana-
lyzed by Western blot using anti-phosphotyrosine antibody. The same
blots were reprobed with anti-Syk antibody. To analyze whether Syk
interacts with Lck and to determinewhetherH/R regulates this process,
cells were exposed to H/R for 45 min. In other experiments, cells were
transfected with wild type and kinase-negative Syk and then subjected
to H/R. Cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.4), 150
mMNaCl, 1%Nonidet P-40, 1%TritonX-100, 1% sodium deoxycholate,
0.1% SDS, 5mM iodoacetamide, 2mMphenylmethylsulfonyl fluoride, 10
g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin). The lysates
containing equal amount of total proteins were immunoprecipitated
with rabbit anti-Lck antibody and analyzed byWestern blot using anti-
Syk antibody. The same blots were reprobed with anti-Lck antibody.
Western Blot Analysis—To analyze the roles of Syk and Lck in regu-
lating MelCAM, VEGF expression, and MMP-9 activation, cells were
transfected with wild type and kinase-negative Syk or dominant-nega-
tive Lck and then exposed to H/R for 24 h as described earlier. The cell
lysates were analyzed by Western blot using anti-MelCAM or anti-
VEGF antibody. The levels of Lck and Syk in nontransfected or trans-
fected cell lysates were also detected by Western blot using anti-Lck or
anti-Syk antibody. The level of activeMMP-9 in conditionedmedia was
detected by Western blot.
To analyze the effect of inhibition of MelCAM on H/R-induced uPA
secretion, cells were pretreated with MelCAM-specific blocking pep-
tide (50 g/ml) for 24 h and subjected to H/R treatment. Cell lysates
were analyzed by Western blot using anti-uPA antibody. The level of
HIF-1 expression in the normal and breast tumor specimens of differ-
ent grades was also detected by Western blot using anti-HIF-1 anti-
body. The same blots were reprobed with anti-actin antibody as loading
control.
Nuclear Extracts andWestern Blot—TocheckwhetherH/R regulates
Sp1 expression, cells were subjected toH/R for 0–180min at 37 °C. The
nuclear extracts were prepared as described earlier (24). Briefly, cells
were incubated in hypotonic buffer (10 mM HEPES (pH 7.9), 1.5 mM
MgCl2, 10 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5 mM
dithiothreitol) and allowed to swell on ice for 10min. Cells were homog-
enized in a Dounce homogenizer. The nuclei were separated by spin-
ning at 3300  g for 5 min at 4 °C. The supernatant was used as cyto-
plasmic extract. The nuclear pellet was extracted in nuclear extraction
buffer (20 mM HEPES (pH 7.9), 0.4 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 25% glycerol, 0.5mMphenylmethylsulfonyl fluoride, and 0.5mM
dithiothreitol) and centrifuged at 12,000  g for 30 min. The superna-
tant was used as nuclear extract. The nuclear extracts were resolved by
SDS-PAGE, and the level of Sp1 was detected by Western blot using
rabbit anti-Sp1 antibody. In separate experiments, to examine the
effects of Syk and Lck on H/R-induced Sp1 expression, cells were trans-
fected with wild type and kinase-negative Syk or DN Lck and then
induced with H/R. The nuclear extracts were prepared and analyzed by
Western blot using anti-Sp1 antibody. The levels of Lck and Syk in
nuclear extracts were also detected by Western blot using anti-Lck or
anti-Syk antibody. The level of expression of HIF-1 in hypoxia or H/R-
induced nuclear extracts was detected by Western blot using anti-
HIF-1 antibody. Actin was used as loading control.
EMSA—To examine whether H/R induces the Sp1-DNA binding, cells
were exposed toH/R for 0–180min as described earlier. To checkwhether
Syk and Lck play any role in regulating H/R-induced Sp1-DNA binding,
cells were transfected with wild type and kinase-negative Syk or pretreated
with Lck inhibitors, pp2 (4 nM), aminogenistein (2M), and damnacanthal
(0.8 M) followed by exposed to H/R for 1 h. The nuclear extracts were
prepared as described above and incubated with 16 fmol of 32P-labeled
double-stranded Sp1 oligonucleotide (5-ATTCGATCGGGGCGGGGC-
3) in binding buffer (25mMHEPES (pH 7.9), 0.5mMEDTA, 0.5mMdithi-
othreitol, 1% Nonidet P-40, 5% glycerol, 50 mM NaCl) containing 1 g of
poly(dI-dC). The DNA-protein complex was resolved on a native poly-
acrylamide gel and analyzed by autoradiography.
InVivoXenograftTumorModel—The tumorigenicity experimentswere
performed as described (47, 48). Briefly, female athymic nudemice, NMRI,
nu/nu (BALB/c) obtained fromNational Institute ofVirology (Pune, India)
were housed under specific pathogen-free conditions and used for in vivo
tumorigenicity studies. Cells were either exposed to H/R or transfected
withwild typeormutantSykand thenexposed toH/R for24h.Cell viability
was determined by the trypan blue exclusion test, and only a single cell
suspensions (5 106/0.2 ml) of90% viability were mixed with Matrigel
and injected subcutaneously into the flanks of female athymic NMRI (nu/
nu)mice (6–8 weeks old). Fivemice were used in each set of experiments.
Growth of tumors was monitored weekly by measuring the tumors with
calipers. The mice were killed after 4 weeks of injection, and the levels of
uPA, VEGF, and MelCAM in the tumors were analyzed by Western blot.
The level of Sp1-DNAbinding in the nuclear extracts of the tumor samples
was determined by EMSA.
The tumor samples were also processed for histopathological studies.
Formalin-fixed paraffin-embedded sections (4 m) were subjected to
antigen retrieval and then stained with rabbit polyclonal anti-MMP-9,
anti-uPA antibody, or mouse monoclonal anti-MelCAM antibody fol-
lowed by FITC-conjugated anti-rabbit or anti-mouse IgG. The tumor
microvessel densities were detected by immunostaining with anti-vWF
antibody. The level of colocalization of Syk and Lck in these tumor
specimens was determined by immunofluorescence using a mixture of
mouse monoclonal anti-Syk and rabbit polyclonal anti-Lck antibody
followed by a mixture of FITC- and TRITC-conjugated IgG. All these
samples were analyzed under confocal microscopy (Zeiss).
Human Breast Tumor Specimen Analysis—Human breast tumor speci-
menswith different grades and normal breast tissueswere collected from a
local hospital with informed consent and were flash-frozen. The immuno-
histochemical and Western blot analyses of those specimens were per-
formed as described above.
RESULTS
H/R Regulates the Cellular Localization of Syk—To determine
whether H/R regulates the cellular localization of Syk,MCF-7 cells (2
105 cells/ml) seeded on 35-mm tissue culture plate were exposed to
hypoxia for 2 h and then reoxygenated for 45 min. After that, cells were
fixed and incubated with rabbit polyclonal anti-Syk antibody followed
by FITC-conjugated anti-rabbit IgG. The data indicated that H/R
induces the cytoplasmic translocation of Syk at 45 min in these cells
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(Fig. 1A). To further confirm the cellular localization of Syk in response
to H/R, cells were exposed to hypoxia for 2 h followed by reoxygenation
for 0–60min. The cytoplasmic and nuclear fractions were isolated, and
the level of Syk was detected byWestern blot. The results indicated that
cytoplasmic translocation of Sykwas found at 45min in response toH/R
exposure (Fig. 1B). The same blots were reprobed with anti-actin anti-
body as loading control. Previous studies demonstrated that HIF-1 is
considered as key transcription factor and acts asmarker under hypoxic
conditions (15). Accordingly cells were exposed to hypoxia for 0–4 h or
exposed to hypoxia for 2 h and then reoxygenated for 0–60 min. The
nuclear extracts were prepared and subjected to Western blot analysis
using anti-HIF-1 antibody. The results indicated that nuclear expres-
sion of HIF-1 was found after 4 h of exposure with hypoxia (Fig. 1C,
lanes 1–5), whereas maximum nuclear expression of HIF-1 was
detected when cells were exposed to hypoxia for 2 h and reoxygenation
for 30 min and rapidly returned to basal level at 60 min (Fig. 1D, lanes
1–5). The level of expression ofHIF-1 in response to hypoxia or reoxy-
genation in nuclear extracts was detected as positive control. Actin was
used as loading control.
H/R Suppresses Syk Phosphorylation—Toascertain the role ofH/R on
tyrosine phosphorylation of Syk, cells were exposed to hypoxia for 2 h
and then reoxygenated for 0–60 min. The cell lysates were immuno-
precipitated with rabbit polyclonal anti-Syk antibody and analyzed by
Western blot using anti-phosphotyrosine antibody (Fig. 2A, upper
panel, lanes 1–5). The data revealed that cells exposed to H/R sup-
pressed tyrosine phosphorylation of Syk at 45min (Fig. 2A, upper panel,
lane 4) and were restored at 60 min (lane 5). These data suggested that
dephosphorylation of Syk at 45 min leads to cytoplasmic translocation,
whereas rephosphorylation causes its nuclear translocation at 60 min
(Figs. 1B and 2A). The same blots were reprobed with anti-Syk antibody
(Fig. 2A, lower panel).
To delineate whether p56Lck plays any role in Syk phosphorylation in
response to H/R, cells were pretreated with Lck inhibitors (pp2, amin-
ogenistein, and damnacanthal) and then treated with H/R. Cell lysates
were immunoprecipitated with anti-Syk antibody and immunoblotted
with anti-Tyr(P) antibody (Fig. 2B, upper panel, lanes 1–5). The same
blots were reprobed with anti-Syk antibody (Fig. 2B, lower panel). The
results indicated that cells treated with Lck inhibitors restored the Syk
phosphorylation, which was down-regulated upon exposure to H/R.
H/R Regulates the Interaction between Syk and Lck—To examine the
role of H/R in regulating the interaction between Syk and Lck, cells were
either exposed to H/R or transfected with wild type andmutant Syk and
then exposed to H/R. Cell lysates were immunoprecipitated with anti-
Lck antibody and analyzed byWestern blot with anti-Syk antibody (Fig.
2C, upper panel). Cells transfected with WT Syk but not with Mut Syk
resulted in restoration of Syk and Lck interaction in response to H/R.
The same blots were reprobed with anti-Lck antibody (Fig. 2C, lower
panel). The cellular colocalization between Syk and Lck in response to
H/R was further confirmed by immunofluorescence study (Fig. 2D).
These results suggested that H/R down-regulates the physical associa-
tion between Syk and Lck, and this is due to cytoplasmic translocation of
Syk in response to H/R at 45 min.
SykNegatively RegulatesH/R-induced Sp1Activation—Todetermine
the role of H/R on Sp1 nuclear translocation and DNA binding, MCF-7
cells were exposed to H/R for 0–180 min as described earlier, and the
cytoplasmic and nuclear extracts were prepared. Nuclear extracts were
subjected toWestern blot using anti-Sp1 antibody (Fig. 3A, upper panel,
lanes 1–5). Similarly, cytoplasmic extracts were also used for Western
blot using anti-Sp1 antibody (Fig. 3A, 2ndmiddle panel). Actinwas used
as loading control (Fig. 3A, 1st middle and lower panels). To examine
whether H/R regulates Sp1-DNA binding, nuclear extracts were ana-
lyzed by EMSA using Sp1-specific oligonucleotide (Fig. 3C, lanes 1–5).
The results showed that H/R induces maximum Sp1 nuclear transloca-
tion and DNA binding at 60 min (Fig. 3, A and C). To examine the roles
of Syk and Lck inH/R-induced Sp1 nuclear translocation and Sp1-DNA
binding, cells were individually transfected with WT and Mut Syk or
DN Lck or treated with Lck-specific inhibitors (pp2, aminogenistein,
and damnacanthal) and were then exposed to H/R. Nuclear extracts
were analyzed by Western blot (Fig. 3B, upper panel, lanes 1–5) and
EMSA (Fig. 3, D and E). The blots were reprobed with anti-Syk or
anti-Lck antibody in order to detect the expression of Syk and Lck (Fig.
3B, 1st middle and 2nd middle panels). Actin was used as loading con-
trol (Fig. 3B, lower panel). The results demonstrated that Syk negatively
regulates H/R-induced Sp1 nuclear translocation and DNA binding,
FIGURE 1. H/R regulates cellular localization of
Syk. A,MCF-7 cells were exposed to hypoxia for 2 h
and reoxygenated for 45 min. The cellular localiza-
tionof Sykwasdeterminedby immunofluorescence
staining using anti-Syk antibody and analyzed by
confocal microscopy. a and b, imunofluorescence
photographs;a’ andb’, phase contrast photographs.
B, cellular localization of Syk was analyzed by West-
ern blot. Cells were exposed to hypoxia for 2 h and
then reoxygenated for 0–60 min. Cytoplasmic and
nuclear extracts were prepared, and the cellular
localization of Syk was detected by Western blot
using anti-Syk antibody. Actin was used as loading
control. Note that maximum level of cytoplasmic
translocationof Sykwasobservedat 45minof expo-
surewithH/R, and its least expressionwasnoticed in
thenucleusat45min.CandD, effectsofhypoxiaand
H/R on nuclear localization of HIF-1. Cells were
exposed tohypoxia for 0–4hor exposed tohypoxia
for 2 h followedby reoxygenation for 0–60min. The
level of HIF-1 in the nuclear extracts was detected
byWestern blot. Note that the higher level of HIF-1
was observed at 4 h of hypoxic treatment or at 30
min of H/R exposure. Actinwas used as loading con-
trol. The results shown here represent three experi-
ments exhibiting similar effects.
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whereas pharmacological or genetic inhibitors of Lck significantly sup-
pressedH/R-induced Sp1 activation, suggesting that Lck and Syk differ-
entially regulate the Sp1 activation in response to H/R.
Syk and Lck Differentially Regulate MelCAM, VEGF, and MMP-9
Expressions in Response toH/R—Todelineate the roles of Syk and Lck in
differentially controlling the expressions ofMelCAMandVEGF and the
activation ofMMP-9 in the presence of H/R, cells were transfected with
DN Lck or WT and Mut Syk and then exposed to H/R. The levels of
MelCAM, VEGF, and MMP-9 were detected by Western blots using
their specific antibodies. The results showed that DN Lck and WT Syk
but not Mut Syk restored the H/R-suppressed MelCAM expression
(Fig. 4A, lanes 1–5). The levels of Lck and Syk expression were also
detected by Western blot analysis using their specific antibodies (Fig.
4A, 1st and 2nd middle panels). Actin was used as loading control (Fig.
4A, lower panel). In contrast, WT Syk and DN Lck suppressed the H/R-
induced VEGF expression and MMP-9 activation (Fig. 4, B, lanes 1–4,
FIGURE 2.A and B, role of H/R in regulation of Lck-dependent Syk phosphorylation.A, cells were exposed to hypoxia for 2 h followedby reoxygenation for 0–60min as described. Cell
lysates were immunoprecipitated with anti-Syk antibody followed by Western blot with anti-phosphotyrosine antibody. The same blot was reprobed with anti-Syk antibody. Note
that significant down-regulation of Syk phosphorylation was observed at 45 min of exposure to H/R. B, cells were pretreated with Lck inhibitors (pp2 (4 nM), aminogenistein (2 M),
and damnacanthal (0.8 M)) and then exposed to H/R. The level of phosphorylated Syk in the cell lysates was detected by Western blot as described earlier. Note that H/R
down-regulates Sykphosphorylation, and inhibitionof Lck restored the Sykphosphorylation in response toH/R.C,H/Rdown-regulates Syk-Lck interaction. Cellswere either exposed
toH/Ror individually transfectedwithWTorMut Syk and then exposed toH/R. Cell lysateswere immunoprecipitatedwith anti-Lck antibody and analyzedbyWesternblot (WB) using
anti-Syk antibody. The sameblotwas reprobedwith anti-Lck antibody. All these bandswere quantified by densitometric analysis, and the fold changeswere calculated.D, role of H/R
in regulation of colocalization between Syk and Lck by immunofluorescence. Note that Syk was stained with TRITC-conjugated IgG, and Lck was stained with FITC-conjugated IgG.
The enhanced colocalizationwas observed at initial stage (control) and restored at 60minofH/R treatment as indicatedbyarrows. However, no colocalizationwas observed at 45min
due to cytoplasmic translocation of Syk. The results shown here represent three experiments exhibiting similar effects.
FIGURE 3. H/R regulates Syk-Lck-mediated Sp1
nuclear translocation and DNA binding. A, cells
were exposed to hypoxia for 2 h followed by
reoxygenation for 0–180 min. The level of Sp1 in
nuclear and cytoplasmic extracts was detected by
Western blot using anti-Sp1 antibody. Actin was
used as loading control. B, cells were individually
transfectedwithWTorMut Syk orDNLck and then
exposed toH/R for 60min as described earlier. The
Sp1 level in the nuclear extractwas determined by
Western blot. The levels of Syk and Lck in the
nuclear extracts were also analyzed by Western
blot using anti-Syk or anti-Lck antibody. The same
blots were reprobed with anti-actin antibody as
loading control. C, experiments paralleling that of
AbutmeasuringSp1-DNAbindingbyEMSA.Dand
E, cells were individually transfected with WT and
Mut Syk or pretreated with pp2 (4 nM) or amin-
ogenistein (2 M) or damnacanthal (0.8 M) and
then exposed to H/R. The Sp1-DNA binding was
performed by EMSA. The results shown here repre-
sent three experiments exhibiting similar effects.
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and C, lanes 1–5). However, cells transfected with Mut Syk further
enhanced the H/R-induced VEGF expression and MMP-9 activation
(Fig. 4, B, lane 3, and C, lane 5). These data suggested that Syk, which is
considered a negative regulator of tumor progression, can also regulate
the expression of MelCAM, a breast tumor suppressor molecule.
MelCAMNegatively Regulates H/R-induced uPA Secretion andMMP-9
Activation—Our previous study demonstrated that uPA plays a crucial
role in MMP-9 activation (47). To examine the role of MelCAM in
regulation of uPA secretion and MMP-9 activation, cells were either
exposed to H/R or pretreated withMelCAM blocking peptide and then
exposed to H/R. Cell lysates were analyzed by Western blot using anti-
uPA antibody. Similarly, the conditioned media were used to detect the
MMP-9 activation by zymography. The results clearly indicated that
H/R enhances uPA secretion and MMP-9 activation, which is further
up-regulated in the presence of MelCAM blocking peptide (Fig. 4, D,
lanes 1–3, and E, lanes 1–3). Our findings clearly demonstrated that a
molecular link exists between Syk/Lck and MelCAM and between
VEGF and MMP-9, and all of these ultimately control the tumor pro-
gression and angiogenesis.
Effect of Syk onXenograftTumorGrowth—Our in vitro results prompted
us to extend our studies to the in vivo system. Accordingly, MCF-7 cells
were transfectedwithWTorMutSyk, exposed toH/R, and then implanted
into the nude mice. After 4 weeks, mice were sacrificed, and tumor speci-
mens were excised. A portion of tumor samples was used for histopatho-
logical studies. The histopathological analysis data indicated thatMut Syk-
transfected tumors showed higher infiltration toward the extravasations,
nuclear polymorphism, andmitotic features compared with the control or
WTSyk-transfected tumors (Fig. 5A,panelsa–c).The immunohistochem-
ical studies were also performed with a mixture of anti-Syk and anti-Lck
antibodies or with anti-MelCAM, anti-uPA, anti-MMP-9, and anti-vWF
antibodies. The data indicated that tumors generated by injectingWTSyk-
transfected cells revealed higher nuclear localization and enhanced inter-
action between Syk and Lck, whereasMut Syk-transfected tumors showed
enhanced cytoplasmic localization of Syk (Fig. 5A, panels d–f). Most inter-
estingly, the expressions of MMP-9, uPA, and neovascularization (vWF
expression) were also higher in the Mut Syk-transfected tumor (Fig. 5E,
panels a–i) that further correlated with our in vitro study. As expected, the
MelCAM expression was higher in WT Syk-transfected tumor (Fig. 5A,
panels g–i).Thiswas also confirmedbyWesternblot analysis (Fig. 5C, lanes
1–3).Western blot data also suggested that the levels of uPA andVEGF are
higher in Mut Syk-transfected tumors (Fig. 5B, lanes 1–3). Similar results
were obtained in Sp1-DNA binding as detected by EMSA (Fig. 5D, lanes
1–3). Thus our studies clearly indicated that Syk acts as a tumor suppressor
and anti-angiogenic candidate gene that differentially regulates MelCAM
expression thatultimately controls uPA-dependentMMP-9activation. Syk
also negatively regulates VEGF expression. These signalingmolecules ulti-
mately control the tumor progression and angiogenesis.
Human Breast Tumor Specimen Analysis—The in vitro and in vivo
mouse model data further prompted us to extend these studies with
human clinical breast tumor samples. Human solid breast tumor spec-
imens were collected with the informed consent from a local hospital.
The tumor grading was determined by histopathology analysis by
hematoxylin and eosin staining using amodified Scarff-Bloom-Richard-
son system, and photographs were taken with a Nikonmicroscope (Fig.
6A, panels a–d). The cellular localizations of Syk and Lck in human
clinical breast tumor sections were detected by incubating with a mix-
ture of anti-Syk and anti-Lck antibodies. Our results indicated that
in normal breast tissue there was colocalization of Syk and Lck, but
with the increasing grade of tumor specimens, no colocalization was
observed. Furthermore, in higher grades of tumors, the expression of
Syk was totally diminished (Fig. 6A, panels e–h). As expected,MelCAM
expression was significantly lower in higher grades of tumors compared
with lower grades or normal tissue (Fig. 6A, panels i–l). The expression
of HIF-1was detected byWestern blot using the same specimens, and
the data showed that the level of HIF-1 was significantly higher in
grade II and III tumors (Fig. 6B, lanes 1–4), which indicated the hypoxic
status in the tumor microenvironment. Higher expressions of MMP-9,
uPA, VEGF, and vWF in these tumor specimens further correlated with
FIGURE 4. Syk-Lck interplay differentially regu-
lates H/R-induced expression of downstream
effector molecules. A, cells were individually
transfected with WT and Mut Syk or DN Lck and
exposed toH/R. The level ofMelCAMexpression in
the cell lysates was analyzed by Western blot. The
levels of Syk and Lck were analyzed by Western
blot. The sameblotswere reprobedwith anti-actin
antibody as loading control. B and C, the expres-
sion of VEGF in the above transfected cell lysates
and the activation of MMP-9 in the above condi-
tioned media were detected by Western blot
using their specific antibodies. Human recombi-
nant VEGF was used as positive control. D and E,
cells were pretreated with MelCAM blocking pep-
tide and then exposed to H/R. The cell lysates and
conditioned media were used to detect the levels
of uPA by Western blot (D) and MMP-9 by zymog-
raphy (E), respectively. Note that H/R down-regu-
lates MelCAM expression but enhances VEGF
expression andMMP-9 activation. BlockingofMel-
CAM by its blocking peptide further stimulates H/R-
induced uPA expression andMMP-9 activation.
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FIGURE5.H/R regulates tumorgrowthandangiogenesis throughdifferential interplaybetweenSykandLck.A,MCF-7 cells (5106/0.2ml)were either exposed toH/R for 24h
or transfectedwithWTorMut Syk and then exposed toH/R. The cell suspensionwasmixedwith coldMatrigel and injected subcutaneously in thedorsal regionofmice. After 4weeks,
tumors were excised and subjected to histopathological analysis by hematoxylin and eosin staining (panels a–c). Note that increased infiltration and nuclear polymorphism were
observed in a tumor generated by injecting Mut Syk but not WT Syk-transfected cells. The physical association between Syk and Lck in these tumors was detected by immunohis-
tochemistry (panels d–f). Note that tumors generated by injecting WT Syk-transfected cells showed higher nuclear localization and enhanced interaction between Syk and Lck,
whereas Mut Syk-transfected tumors showed enhanced cytoplasmic localization of Syk (panels d–f). Syk was stained with FITC-conjugated IgG (green), and Lck was stained with
TRITC-conjugated IgG (red). The nuclei of the cells was visualized by DAPI (blue) staining. The MelCAM expression in these tumors was analyzed by immunofluorescence using
anti-MelCAMantibody (panels g–i). B andC, the expressions of uPA, VEGF, andMelCAM in the tumor extractswere also analyzedbyWestern blot using their specific antibodies.D, the
Sp1-DNA binding in the nuclear extracts was performed by EMSA. E, the levels of uPA, MMP-9, and vWF in the above tumor specimens were analyzed by immunofluorescence using
their specific antibodies (panels a–i). Note that there was drastic reduction in uPA andMMP-9 levels in a tumor generated by injectingWT Syk but not Mut Syk-transfected cells. The
microvessel density was detected by staining with anti-vWF antibody (endothelial cell-specific marker) in these tumors (panels g–i). The nuclei were stained with DAPI (blue). The
enhanced vWF expression observed in Mut Syk-transfected tumors indicated higher vascularization compared with control or WT Syk-transfected tumors.
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higher grades (Fig. 6C, panels a–p). Taken together, our data indicated
that the Syk andMelCAM act as a negative regulator of tumor progres-
sion and angiogenesis and can act as a potential therapeutic target in
breast cancer.
DISCUSSION
Our study indicated that Syk and Lck play a crucial regulatory factor
in hypoxia-induced tumor progression and angiogenesis. The data also
demonstrated that Syk acts as a negative regulator of H/R-induced
tumor progression, whereas Lck as a positive regulator, and H/R plays a
pivotal role in regulating the cross-talk between Syk and Lck. Our pre-
vious study indicated that inhibition of Syk activity by Syk-specific anti-
sense S-oligonucleotide resulted in enhanced uPA expression and cell
motility in MCF-7 cells (23). In this study, we showed that H/R plays a
crucial role in inactivation of Syk by inhibiting its phosphorylation,
thereby resulting in its cytoplasmic translocation. Furthermore, the data
indicated that the physical association between phosphorylated Syk and
Lck in the nucleus resulted in inactivation of Lck. Upon H/R treatment
FIGURE 6. Immunohistochemical analysis of
human breast tumor specimens of different
pathological grades. A, normal and tumorigenic
human breast specimens were collected from a
local hospital with informed consent, and the gra-
dations of these samples were performed using a
modified Scarff-Bloom-Richardson system (panels
a–d). Expression and cellular colocalization of Syk
and Lck were analyzed by immunohistochemistry
(panels e–h). Syk was stained with FITC, and Lck
was stained with TRITC, and colocalization was
visualized as yellow. The nuclei were stained with
DAPI (blue). Note that in normal breast tissue the
cellular colocalization of Syk-Lck was observed.
The expression of both Syk and Lckwere observed
in grade I tumor. However, Lck but not Syk expres-
sion was observed in tumors of higher grades
(grades II and III). There was significant expression
of MelCAM in normal and lower grade tumors but
was significantly diminished in tumors of higher
grades (panels i–l). B, hypoxic level of these speci-
mens was determined from the tumor lysates by
Western blot analysis using anti-HIF-1 antibody.
Actin was used as loading control. C, expression
levels of MMP-9 (panels a–d), uPA (panels e–h),
VEGF (panels i–l), and vWF (panels m–p) were ana-
lyzed by immunohistochemistry using their spe-
cific antibodies. Note that the expression status of
all of these molecules was significantly enhanced
in higher grades of tumors.
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the phosphorylation of Syk was abrogated, which in turn resulted in the
dissociation of Syk from Lck leading to activation of Lck, which ulti-
mately targets downstream signaling events.
Previous studies indicated thatMelCAMact as a tumor suppresser in
breast carcinoma (32). This prompted us to investigate whether H/R
regulates Syk/Lck-mediated MelCAM expression in MCF-7 cells. Our
data indicated that H/R down-regulates the expression of MelCAM,
which was restored upon transfection of cells with WT Syk or DN Lck.
Our findings established a crucialmolecular link between the two breast
cancer-specific tumor suppressor molecules, Syk and MelCAM. The
data clearly indicated that Syk enhances and Lck inhibits MelCAM
expression, and thus both ultimately regulate breast cancer progression.
Moreover, H/R-induced expressions of MMP-9 and VEGF were sup-
pressed upon overexpression of Syk or inactivation of Lck. Thus Syk
exerts its tumor-suppressive effect either through induction of Mel-
CAM expression or suppression of tumor promoters like uPA,MMP-9,
and VEGF. On the other hand, Lck activated upon H/R treatment,
which enhances breast tumor progression through suppression of Mel-
CAM expression and induction ofMMP-9, uPA, and VEGF expression.
Interestingly, the data also showed that blocking of MelCAM using its
specific blocking peptide also resulted in induction of uPA as well as
MMP-9 expression and activation. The data further indicated that Syk
suppresses tumor progression through regulation of MelCAM-medi-
ated mechanism.
Sp1 is a ubiquitously expressed transcription factor that recognizes
GC-rich sequences present in the regulatory sequences of numerous
housekeeping genes and those genes that are involved in growth regu-
lation and cancer (34, 45). The transcription factor Sp1-response ele-
ment is present in the promoter region of various genes, including uPA,
MMP-9, and VEGF. Sp1 is one of the key transcription factors, and its
activation occurs under hypoxic conditions in various cancer cells,
including breast carcinoma (34, 36, 45). In our study, we have demon-
strated that H/R-regulated cross-talk between Syk and Lck controls
nuclear localization and DNA binding of Sp1. Furthermore, Syk nega-
tively and Lck positively regulates Sp1 activation. Therefore, H/R
through a Syk-Lck-mediated pathway controls Sp1 activation and reg-
ulates the expression of downstream molecules such as uPA, MMP-9,
VEGF, and MelCAM that promotes tumor growth and angiogenesis
(Fig. 7).
Our in vivo and clinical specimen analysis clearly supports our
in vitro findings. In a xenograft study, tumors generated by injecting
wild type Syk-transfected cells significantly suppressed the tumor
growth, whereas mutant Syk-transfected cells showed enhanced tumor
growth. The levels of uPA, MMP-9, VEGF, as well as microvessel den-
sity were significantly reduced, whereas the physical interaction
between Syk and Lck and expression of MelCAM were significantly
enhanced inwild type but not inMut Syk-transfected tumors. In clinical
specimen analysis, we observed that in higher grades of tumors (grade II
and III), the level of HIF-1 is significantly higher, which indicated the
enhanced hypoxic condition in tumormicroenvironment. The low level
of HIF-1 was observed in normal breast tissue and in lower grades of
tumor. There was significant expression of Syk in normal breast tissues
and lower grades of tumor. However, the physical association between
Syk and Lck was observed in normal breast tissues. Moreover, the
increased expression of Lck but not Syk was visualized in higher grades
of tumors. Furthermore, the higher grades of tumors showed enhanced
expression of uPA, MMP-9, and VEGF, and the increased microvessel
density was also characterized in these tumors. In addition, the Mel-
CAM expression was significantly diminished in tumors of higher
grades that corroborated with both in vitro and in vivo findings.
In summary, to our knowledge, this is the first report that H/R differ-
entially regulates the cross-talk between Lck and Syk, which ultimately
control tumor progression. Previous reports have indicated that an
increased hypoxic or consecutive hypoxia/reoxygenation condition in
the tumor microenvironment plays a crucial role in determining the
oncogenic potential of various cancers. Therefore, an in-depth under-
standing of theH/R-regulated signalingmechanismmay be beneficial in
designing a novel therapeutic approach for the treatment of cancer.We
have shown that Syk, a tumor suppressor, positively regulates the
expression of the breast cancer-specific tumor suppressor MelCAM.
Interestingly, overexpression of Syk inhibits H/R-induced expression of
several tumorigenicmolecules, including uPA,MMP-9, andVEGF.Our
results indicate that the mechanism demonstrated in the mouse model
underlies human pathology, and a clear understanding of such mecha-
FIGURE 7. Molecular mechanism of H/R-regu-
lated cross-talk between Syk and Lck that con-
trols breast tumorprogression andangiogene-
sis. H/R suppresses Syk phosphorylation leading
to its cytoplasmic translocation. This results in acti-
vation of Lck, which initiates the various down-
streamsignalingevents. Lck in response toH/R stim-
ulates Sp1 activation leading to enhanced uPA,
MMP-9, and VEGF expressions but suppression of
MelCAM expression, which ultimately stimulates
breast carcinoma progression and angiogenesis.
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nisms may facilitate the development of novel therapeutic approaches
to suppress hypoxia/reoxygenation-regulated Syk/Lck-mediated uPA,
MMP-9, and VEGF expression, thereby controlling tumor growth and
angiogenesis.
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